Navigation Links
B. Braun Obtains Permanent Injunction
Date:5/4/2011

BETHLEHEM, Pa., May 4, 2011 /PRNewswire/ -- Germany-based medical device manufacturer B. Braun Melsungen AG and its U.S. subsidiary B. Braun Medical Inc. (B. Braun) announced today that the company succeeded in obtaining a permanent injunction in its patent infringement case against Japan's Terumo Corporation and its U.S. subsidiary Terumo Medical Corporation.

(Logo:  http://photos.prnewswire.com/prnh/20081022/NYW008LOGO)

On April 21, 2011, the U.S. District Court for the District of Delaware granted an immediate and permanent order, stopping Japan's Terumo Corporation and its U.S. subsidiary Terumo Medical Corporation from selling, or offering to sell, the Surshield® Safety IV Catheter in the acute care market, and precluding Terumo from bidding against B. Braun on expiring GPO contracts. Terumo will be permitted to continue selling the Surshield Safety IV Catheter into the alternative care market until June 1, 2012 after which it cannot make, sell, use or offer the Surshield Safety Catheter in the U.S.  B. Braun will seek damages and other relief for Terumo's infringement.

B. Braun's win follows a previous verdict awarded in November 2010, confirming the validity of an infringed claim of B. Braun's 2007 patent (U.S. Patent 7,264,613) for its Introcan Safety® IV Catheter.

About B. Braun's Introcan Safety® IV Catheter

B. Braun's Introcan Safety® IV Catheter, a passive, fully automatic safety device, designed to help protect against accidental needlestick injuries (NSIs). NSIs and other sharps injuries expose hundreds of thousands of healthcare providers each year to serious blood borne pathogens like hepatitis C and HIV. With the Introcan Safety® IV Catheter, the safety device is activated automatically and cannot be bypassed.

A recent landmark study conducted by GERES (Groupe d'Etude sur le Risque d'Exposition des Soignants) of 22 million safety devices used in 61 French hospitals over a two-year period has confirmed the theory that passive, fully automatic safety devices like B. Braun's Introcan Safety® IV Catheter offer significantly better protection against NSIs than early generation active safety technologies such as semi-automatic (push-button) devices or those with manually sliding shields or hinged caps.

For more information about B. Braun's Introcan Safety® IV Catheter visit http://introcansafety.bbraunusa.com.  

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy,

B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, email us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.


'/>"/>
SOURCE B. Braun
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Offers Wound Patients a New Over-the-Counter Wound Management Gel - Prontosan®
2. B. Braun Voluntarily Recalls Seven Lots of Heparin Manufactured in 2008 Due to Supplier-Initiated Recall of Heparin Active Pharmaceutical Ingredient (API)
3. B. Braun Wins Third Consecutive Safety IV Catheters Contract Award from Premier, Inc.
4. FDA-Approved Cefepime Now Available for Use in B. Brauns DUPLEX® System
5. B. Braun Customers Gain Premier Access to Zynx Health Device Networks Evidence-based, Customizable Drug Library Program
6. B. Braun Large Volume Heparin Infusion Solutions Now Available
7. New Technology Center Increases B. Brauns Infusion Pump Capacity
8. Health Robotics Re-Acquires CytoCares European Rights from B. Braun Melsungen AG for Undisclosed Consideration
9. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
10. B. Braun Renal Therapies Division Announces Availability of Adimea
11. B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):